Syngene International, a global integrated research, development, and manufacturing services company, will be exhibiting at CPHI Worldwide 2024 in Milan, Italy, at Booth #7C114, from 8-10 October.
With more than three decades of experience, 400+ active global clients and 400+ patents held with clients, Syngene offers end-to-end services from preclinical to commercial across modalities.
What makes Syngene the preferred CRO-CDMO partner?
- India advantage: Headquartered in India, we offer the benefits of cost-efficiency and supply stability. We have a network of 2500+ suppliers spread across 30+ countries, flexible manufacturing capacity, and world-class scientists to support your R&D programmes.
- End-to-end services: Our scientific solutions are across therapeutic areas and modalities, including small molecules, biologics, oligonucleotides and peptides.
- Manufacturing: We offer flexible manufacturing capacity, including custom manufacturing from our USFDA, and EMA-approved facilities – 70,000l for small molecules and 28,000l (expandible to 48,000l) for biologics. We also have a high-speed fill-finish facility with a capacity of one million vials/day.
- Biologics: Our ongoing expansion in capabilities and capacity in Biologics has established Syngene as one of the largest CRDMOs in India. As a trusted partner, we have delivered 100 commercial batches in the last two years. Our track record of over 250 GMP batches, 150+ projects, and support for over 25 INDs across biologics modalities demonstrates our expertise.
- Sustainability: Our continuous commitment to excellence in environmental, social and governance (ESG) practices has resulted in the company securing a silver rating in the prestigious EcoVadis sustainability index for FY2024, placing us among the top 15% of assessed companies.
For more information about Syngene’s participation in CPHI Milan or to book a meeting with our experts, click here.